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Olfactory ensheathing cells (OECs) promote axonal regeneration and improve locomotor function 
when transplanted into the injured spinal cord. A recent clinical trial demonstrated improved motor 
function in domestic dogs with spinal injury following autologous OEC transplantation. Their utility 
in canines offers promise for human translation, as dogs are comparable to humans in terms of clinical 
management and genetic/environmental variation. Moreover, the autologous, minimally invasive 
derivation of OECs makes them viable for human spinal injury investigation. Genetic engineering of 
transplant populations may augment their therapeutic potential, but relies heavily on viral methods 
which have several drawbacks for clinical translation. We present here the first proof that magnetic 
particles deployed with applied magnetic fields and advanced DNA minicircle vectors can safely 
bioengineer OECs to secrete a key neurotrophic factor, with an efficiency approaching that of viral 
vectors. We suggest that our alternative approach offers high translational potential for the delivery of 
augmented clinical cell therapies.  
  
INTRODUCTION 
Spinal cord injury  (SCI) can result in paralysis and reduction in  patient  quality  of  life,  with  high  
associated healthcare costs.1 Transplantation  of olfactory ensheathing cells (OECs) into  sites of SCI 
has been identified  in  multiple  pre-clinical studies  as  a  potential   regeneration  promoting   
strategy;2–5 offering high translational  benefits due to ease of autologous cell derivation (using 
minimally invasive endoscopic surgery6). Crucially, a clinical trial in companion dogs with chronic 
naturally occurring thoracic SCI (e.g. degenerative disc prolapse) conducted in Cambridge in 2012, 
demonstrated improved locomotor recovery after transplantation of autologous nasal mucosa-derived 
OECs and fibroblasts versus controls.7 This study is of significant interest for human applications as a 
large animal model of SCI, offering critical similarities to clinical SCI in humans in terms of lesion 
heterogeneity and pathogenesis. Indeed, safety trials since 2005 have established the therapeutic 
potential of OEC transplantation in human patients8–11 and these have been accompanied by at least 
one high profile clinical case in Poland in which OEC transplantation into a site of complete spinal 
cord transection was followed by restoration of lower limb movement.12 
 
However, improving the therapeutic capacity of OECs is a key clinical goal. For example, in the 
canine trial, secondary outcome measures including kinematic evaluation of brain controlled 
coordination did not indicate recovery of complex/brain-derived neurological functions.7 Although 
the study was not powered to detect changes of these functions, it did not support evidence for long 
tract regeneration and restoration of cortical control. Genetic engineering of OECs for release of 
neurotrophic factors at injury sites offers a potential strategy for improved regenerative outcomes;13,14 
for example, OECs genetically modified to secrete neurotrophin-3 (NT-3) and glial cell line-derived 
neurotrophic factor (GDNF) show improved functionality post-transplantation versus non-engineered 
OECs.15–17 Whilst work is ongoing to improve the safety of viral vector mediated bioengineering 
approaches, they can be associated with significant oncogenic18 and inflammatory19 risks to recipients. 
Along with safety issues, there are also challenges in pharmaceutical scale-up of viral engineering 
approaches,20 meaning difficulties still remain in translating virally engineered OECs into the clinic. 
 As an alternative, we have previously shown that iron oxide magnetic particle (MP) vectors deployed 
with applied magnetic fields (‘magnetofection’) can safely engineer major rodent neural transplant 
populations including neural stem cells (NSCs) and oligodendrocyte precursor cells (OPCs).21–23 MPs 
also offer key advantages in non-invasive transplant cell tracking in host tissue using standard 
neuroimaging technologies widely available within healthcare systems.26 Optimizing MP based 
transfection procedures for transplant cells could therefore have critical importance with respect to 
MP mediated cell tracking if using appropriately designed particles (capable of transfection and MRI 
contrast generation).27 This would be of high value to one-step combined transfection and tracking 
protocols for cell transplant populations, offering further benefits over other means of gene delivery. 
Further, the approach can be flexibly combined with advanced DNA minicircle (mC) vectors to safely 
deliver reporter/therapeutic genes to NSCs with similar efficiencies to viral vectors.24,25 Despite the 
translational promise of this approach, application of this fusion of novel technologies to clinical cell 
populations has never been tested. 
 
This study investigates the utility of the MP platform deployed with magnetic fields and mC DNA 
vectors for safe genetic engineering of canine OECs (cOECs), with a view to exploiting the 
technology in future canine transplantation trials. We have used banked cOECs derived for the 
Cambridge canine transplantation trial (which have pre-documented cellular characterisation and 
related records of clinical outcomes following transplantation). The aims of this proof of concept 
investigation were to: (i) develop optimised magnetofection protocols for gene delivery to cOECs 
using reporter plasmids; and (ii) use the optimised protocols to engineer cOECs to express a major 
neurotherapeutic protein-brain derived neurotrophic factor (BDNF) using mC vectors. 
 
EXPERIMENTAL 
Neuromag and mC complex characterization details 
Neuromag is a commercially available transfection grade MP marketed by Oz Biosciences with a 
proprietary formulation. We have previously shown that the size of the naked MPs is ca. 300 nm 
(polydispersity index of 0.2) in DMEM which increases to ca. 900 nm (polydispersity index of 0.24) 
with the addition of the mC construct encoding BDNF.25 The zeta potential of the resulting complex 
was shown to be 5.5 mV.25 At the chosen ratio of 3.5 μL Neuromag to 1 μg DNA we have also shown 
that the entire DNA amount is associated with the particles.28 
Primary canine olfactory mucosal cell (cOMC) culture 
An OEC bank was generated during the clinical trial for OEC transplantation into sites of SCI in 
companion dogs7 and used to generate the primary cOMCs used for all experiments. The cells were 
obtained as part of a protocol reviewed and approved by the Royal College of Veterinary Surgeons 
and the Ethical Review Committee of the Department of Veterinary Medicine, University of 
Cambridge. Details of recruitment and cell harvest methodology have previously been published.7,29 
Magnetofection of cOMCs 
Cells (passages 0–11) were seeded (1 × 105 cells per mL; 0.6 mL) on to PDL-coated coverslips in 24-
well plates. After 24 h, the media in each well was replaced with fresh media (0.225 mL) and the plate 
returned to the incubator for a minimum of 2 h. To prepare nanoparticle complexes, 88 ng pmax-GFP 
was mixed with 0.31 μL Neuromag in 75 μL DMEM, corresponding to a Neuromag : DNA ratio of 
3.5 μL μg−1. After 20 min, 75 μL complexes were added to each well (controls were DMEM alone) 
and plates were exposed to their respective magnetic field condition for 30 min. These were: no field, 
static field (F = 0 Hz), and oscillating fields of F = 1 Hz and F = 4 Hz. Control wells were not 
exposed to a magnetic field. Cells were then removed from the magnetic array and returned to the 
incubator for 24 h prior to fixing. To transfect cells with minicircles encoding BDNF (herein termed: 
mC-BDNF-GFP) the procedure was performed in an identical manner, using only a single optimum 
magnetic field condition and control. 
mC vector formulation 
The mC construct was prepared as previously described.25  Briefly, ‘parental plasmids’ are 
transformed in ZYCY10P3S2T Producer Bacterial Strain, a specifically engineered E. coli strain 
which upon addition of arabinose express two enzymes: (i) ΦC31 integrase – which splits the parental 
plasmid into two circular entities, mC-DNA (size: 4.1 kb), and the bacterial backbone containing SceI 
endonuclease recognition sequence (size: 4.0 kb) and (ii) SceI endonuclease which degrades the 
bacterial backbone sequence. This leaves the mC-DNA which was extracted using an Endotoxin-free 
maxiprep kit (Qiagen, UK). 
Analysis of MP uptake, transfection efficiency and safety of magnetofection 
Cells were analysed at 24 h post transfection to assess transfection efficiency, particle uptake and 
measures of protocol safety. LIVE/DEAD staining was performed by incubating cells for 15 min in 
DMEM containing 4 μM calcein AM (green fluorescence in live cells) and 6 μM ethidium 
homodimer-1 (red fluorescence in dead cells). Remaining cells were fixed in 4% paraformaldehyde 
and stained with primary antibodies for p75 and Fn for Neuromag-GFP transfection and GFP and 
BDNF for mC-BDNF-GFP transfection. Merged fluorescent and phase images were used to estimate 
MP uptake, transfection efficiency and pyknotic nuclei. A Click-iT® EdU (a nucleoside analogue of 
thymidine incorporated in to DNA during active DNA synthesis) assay was performed to estimate 
numbers of proliferating cells by adding the EDU reagent 6 h prior to fixing and detection in fixed 
cells by fluorescent labelling. Immunostaining for copGFP (naturally occurring GFP with low 
fluorescence intensity) was used in the mC-BDNF-GFP experiments to enhance fluorescence for the 
purpose of cell counting. To assess transfection efficiency/success of the mC vector, cells were 
stained with primary antibodies for GFP and BDNF with GFP positive cells scored as transfected. 
Transfected cells were classified based on immunostaining and morphology and adapted from 
previous descriptions.30 To determine the BDNF protein concentration in cell supernatants, an ELISA 
was applied using the Quantikine® ELISA Kit (R&D Systems, UK) according to the manufacturer’s 
instructions. 
Phase and fluorescence microscopy 
Phase and fluorescence microscopy of all experiments was performed using an Axio Observer.Z1 
equipped with an AxioCam MRm powered by Zen 2 (blue edition) software (Carl Zeiss 
MicroImaging GmbH, Goettingen, Germany). Images were merged and quantified using ImageJ 
1.49v software. 
Statistical analyses 
For pmax-GFP transfection, all data were analysed by a one-way ANOVA with statistical differences 
determined by Bonferroni’s multiple comparison test (MCT). For mC-BDNF-GFP transfection data 
were analysed using an unpaired t-test. In both cases, statistical differences were determined using 
Prism software (version 6.0). Data is expressed as mean ± standard error of the mean and the number 
of experiments ‘n’, refers to the number of independent cultures used. In this case, independent means 
different cell cultures each of which is derived from a different companion dog. 
RESULTS 
Field application enhances MP uptake and transfection efficiency in cOMCs 
Primary cOMC populations were successfully recovered from frozen tissue banks and displayed 
normal morphologies and good adherence to the substrate (see ESI Fig. 1† for characterization). A 
‘safe’ particle dose of 0.31 μL per well or 1.05 μL mL−1 was established here at which uniform 
cellular morphologies with no obvious rounding or detachment could be observed (Fig. 1A and B). 
Particles tended to be localised in the cell body, with almost no particles visible in cell processes (Fig. 
1A and B). Under no field, the ‘baseline’ particle uptake was 86.0 ± 0.8% (range 85.0–87.2%; Fig. 1A 
and C), and significantly increased to 94.8% ± 1.6% when a static magnetic field was applied (range 
91.8–99.3%; Fig. 1B and C). Application of oscillating fields significantly enhanced labelling versus 
no field but with no enhancement over the static field condition (Fig. 1C). 
Expression of GFP was observed in all experimental conditions in both OEC and fibroblast-like cells, 
with uniform expression throughout transfected cells (Fig. 1D and E). Baseline transfection efficiency 
in the no field condition was 34.9 ± 2.9% (range 28.8–42.7%; Fig. 1D and F) and increased to 57.7 ± 
3.5% (range: 48.8–63.9%; Fig. 1E and F) in the static field condition. In line with particle uptake, 
application of oscillating magnetic fields significantly enhanced transfection over the no field 
condition but with no further improvements over the static field (Fig. 1F). Of the transfected cells 
across all conditions, 47.6 ± 3.1% displayed a bipolar fusiform morphology and p75 staining 
(classified as OECs); 29.3 ± 6.0% displayed fibroblast-like morphologies with strong Fn staining and 
23.1 ± 3.5% could not be characterized phenotypically. 
Magnetofection protocols had no effect on parameters of cell health 
Magnetofected cultures displayed similar numbers of proliferating cells to control conditions, as 
measured by Click-iT® EdU proliferation assay, with GFP expressing cells also staining positive for 
the proliferation marker (Fig. 2A and D). Further, all conditions displayed similar and high viability 
(>95%) using a Live/Dead assay (Fig. 2B and E). Finally, the level of pyknosis (condensed and 
fragmented nuclei often a marker of cell death) was low and did not differ between experimental 
conditions, remaining below 2% in all conditions (Fig. 2C and F). 
Rationale for selection of optimal magnetic field condition: delivery of mCs encoding BDNF 
Overall, particle uptake and GFP expression did not differ significantly between conditions exposed 
to a magnetic field. Additionally, there was no evidence of differences in cellular viability and 
proliferation between experimental conditions. However, static magnets are considerably cheaper, do 
not require dedicated infrastructure, utilise technically facile protocols and are more readily available 
than oscillating magnetic arrays. As such, they have a greater practical relevance to magnetofection 
protocols performed in a clinical setting. Therefore, the static field was taken as the optimum field 
condition for transfection with mC-BDNF-GFP. 
GFP staining successfully enhanced detection of GFP expressing cells (Fig. 3A) and transfection 
efficiency using mC-BDNF-GFP was estimated to be 8.1 ± 0.3% (range: 7.5–8.7%). Additionally, 
immunostaining for BDNF revealed a punctate pattern of fluorescence within GFP+ cells suggesting 
intracellular vesicular storage of BDNF (Fig. 3B). There was also some weak BDNF staining visible 
within cells that did not express GFP (Fig. 3B), implying endogenous BDNF expression in cOMCs. 
However, mC-BDNF-GFP magnetofection resulted in a three-and-a-half-fold increase in the mean 
concentration of BDNF in cell supernatant versus controls (Fig. 3C) as determined by ELISA. Safety 
assays revealed that there were no significant differences between mC-BDNF-GFP transfected and 
untransfected control cells in terms of the percentage of proliferating cells, cell viability or percentage 
of pyknotic nuclei (Fig. 3D–F). 
DISCUSSION 
We demonstrate for the first time that non-viral MP based platforms in conjunction with 
magnetofection technology can safely and efficiently engineer cOMC populations, previously derived 
clinically for transplantation into dogs with SCI. Further, the approach could be combined with 
advanced mC-DNA vectors, which offer major translational advantages in terms of safety and 
enhanced gene expression, to successfully engineer cOMCs to secrete BDNF. We therefore suggest 
that these techniques may be adopted in future cOMC clinical trials in canines as an alternative to 
viral modification, a technique that has several regulatory hurdles preventing its widespread adoption. 
Compared with previous reports, the transfection levels we have obtained for cOMCs appear to be 
within ranges reported for viral methods: Carwardine et al.17 reported a maximum transduction 
efficiency of 34% at a multiplicity of infection (MOI) of 10, using chondroitinase ABC encoding 
lentiviral vectors and Ruitenberg et al.31 reported 100% transduction of rodent olfactory bulb-derived 
OECs with a reporter plasmid at an MOI of 50 and 100 using lentiviral and adenoviral vectors, 
respectively. Wu et al.32 transfected purified rodent olfactory bulb-derived OECs with a plasmid 
encoding NT-3 using a commercial lipofection agent, reporting a maximum transfection efficiency of 
30% showing our techniques also compare favourably with other non-viral methods. It is worth 
noting that the cOMC transfection levels obtained with reporter plasmids are the highest we have 
achieved to date (in a transplant population for neurological applications) using magnetofection (Fig. 
4), implying a high permissivity of this population to bioengineering approaches. High transfection 
levels were achieved with a static field alone, whereas other cell types required application of 
specialized and expensive oscillating field equipment, offering further translational benefits. 
Our ELISA analysis confirms that BDNF secretion from cOMC grafts could be enhanced threefold 
through MP mediated engineering approaches. BDNF is a key regenerative molecule and can promote 
local axonal sprouting and neuronal plasticity at CNS injury foci (reviewed by Weishaupt et al.33) 
indicating the potential to augment transplantmediated therapeutic capacity. Whilst BDNF secretion 
was markedly enhanced in engineered cells, the proportion of transfected cells was relatively low (ca. 
8%). Two reasons could account for this: (i) a small number of cells secreting high levels of BDNF 
due to cellular heterogeneity in uptake of particle–plasmid complexes; or (ii) dissociation occurring at 
the transcription/translation level between the gene encoding BDNF and the downstream GFP gene – 
a well know issue with the internal ribosome entry site technology employed in the mC vectors.34–36 If 
necessary, fluorescence-activated cell sorting could be utilized to purify transplant populations37,38 in 
the future, in order to enhance the proportions of engineered cells in the grafts. 
The mC technology used here offers several critical advantages for safe genetic engineering for 
clinical applications.24,25 The removal of bacterial components found in conventional plasmids 
(including antibiotic resistance genes and an origin of replication) reduces numbers of unmethylated 
CpG motifs that can induce the host inflammatory response.39 As such, regulatory bodies advise that 
use of antibiotic resistance genes should be limited where possible, particularly as their administration 
can limit other treatment options.39–42 Absence of a bacterial backbone also mitigates gene silencing 
events, so mC technology can confer prolonged transgene expression versus conventional plasmids.24 
Additionally, the relatively small size of mCs (1.6 kb) could allow for incorporation of therapeutic 
genes such as that encoding chondroitinase ABC (insert size: 2 kb), without significantly reducing 
transfection efficiency. Additional neurotrophic genes (typical open reading frames of 1.2 kb) could 
also be inserted in place of the GFP reporter sequence (size ca. 756 bp), without appreciably 
increasing construct size. It is noteworthy that in light of the clinical utility of mC constructs, a novel 
method of obtaining highly purified mC-DNA for clinical applications such as gene therapy and 
vaccination has been developed involving affinity based chromatography, which enables safe 
production of mCs at an industrial scale.43–45 
CONCLUSION/FUTURE DIRECTIONS 
We have demonstrated that mixed cOMC populations can be engineered to serve as biopumps for 
delivery of neurotherapeutic factors. In the context of developing a safe and effective therapy for SCI, 
we consider that the combination of advanced methodologies utilised here offers several clinical 
translational advantages. OECs are a promising clinical population due to their relatively 
straightforward autologous derivation and their proven potential in promoting repair after SCI. 
Further, engineering OECs using the MP platform and advanced mC vector technology seems 
particularly advantageous given the efficient particle uptake by OECs and the lack of detectable 
effects on cell health. This means that the additional benefits provided by the MP platform, such as 
the use of bimodal nanoparticles for simultaneous gene delivery and imaging27 could be safely 
exploited. Future work will deploy this therapy in vivo in clinical spinal injuries (including in canine 
trials), and explore the ability of this technical approach to deliver other genes involved in repair such 
as additional neurotherapeutic factors to promote growth, chondroitinase ABC to degrade the glial 
scar,17,46 and VEGF to promote local angiogenesis.47 
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FIGURES 
Figure 1 : Magnetic field application increases particle uptake and transfection efficiency. (A&B) 
Representative fluorescent/phase images showing fluorescent Neuromag uptake in the (A) no field 
and (B) static field condition. (A-inset) Representative fluorescent/phase image showing abnormal 
cellular morphologies when magnetofection was attempted with 2.1 μL mL−1 Neuromag. Note cell 
rounding, retraction of processes and detachment. Scale bar in inset is 25 μm. (C) Graph showing 
quantification of the proportions of cells which displayed nanoparticle uptake. (D&E) GFP expression 
in (D) no field and (E) static field conditions with GFP+ fibroblasts depicted in the insets. (F) Graph  
showing quantification of the proportion of transfected cells in each field condition. **P < 0.01 versus 
no field. n = 4, one-way ANOVA and Bonferroni’s MCT. NF – no field. 
 
  
Figure 2. Cellular viability and proliferation were unaffected by magnetofection protocols. (A) 
Representative double merged fluorescent image of EdU+ GFP+ cells in the static field condition. 
Two adjacent, transfected EdU+ cells (arrow) suggest recent division. (B) Representative double 
merged image of Live/Dead staining in the static field condition showing high numbers of live (green) 
cells with a small proportion of dead (red) cells (arrow). (C) Representative fluorescent and phase 
merged image of a cell displaying typical pyknotic nuclei with condensation and nuclear 
fragmentation. (D–F) Graphs showing quantification of (D) the percentage of cells positive for EdU, 
(E) the percentage of live cells and (F) the percentage of cells which displayed pyknotic 
characteristics across all conditions. n = 4. NF – no field. 
 
  
Figure 3. MPs can effectively deliver mC-BDNF-GFP to cOMCs, with no effect on cellular viability 
or proliferation. (A) Representative fluorescent images showing GFP staining enhances copGFP 
fluorescence (inset). (B) Representative triple merged fluorescent image showing BDNF 
accumulation inside transfected cells (inset – counterpart double merged image just showing BDNF 
staining). Note small quantities of BDNF inside adjacent untransfected cell. (C) Graph showing 
concentration of BDNF in cOMC culture supernatant in both conditions. (D–F) Graphs showing 
quantification of (D) percentage of cells positive for EdU, (E) percentage of live cells and (F) 
percentage of cells which displayed pyknotic characteristics across both conditions. *p < 0.05 versus 
control, unpaired t-test, n = 3. 
 
  
Figure 4. cOMCs show a greater permissiveness for transfection than NSCs and OPCs. Graph 
displaying how transfection efficiency in cOMCs compares to that seen in other neural cell 
populations for which we have developed optimised magnetofection protocols. Adapted from ref. 22, 
23, 31 and 32. 
 
